ExpreS2ion Biotechnologies partner Bavarian today announced an updated design and trial design for the Phase 3 covid-19 candidate. The Phase 3 is now expected to start August 2022, againt the earlier timeline stated H1 2022; however, crucially the data read-out will stay before year end 22. On the positive side, the trial now will include a licensed mRNA vaccine named Comirnaty® (Pfizer/Biontech) as a comparator, thereby showing non-inferiority to a licensed vaccine. This will give more robust data and a better chance to show advantages to current vaccines (standard treatment). The share is down 3% today, less than the general biotech sector, so the market might weigh the advantage on the study’s design higher than the small delay.